British drugmaker AstraZeneca has agreed to pay more than $5 million to settle allegations that it broke US anticorruption laws in China and Russia. The Securities and Exchange Commission said late Tuesday that in China, employees of an AstraZeneca subsidiary offered cash and gifts to health care officials to encourage them to buy AstraZeneca drugs or reduce pending financial sanctions. In Russia, AstraZeneca also promoted drug sales through improper payments, it said.
The announcement makes AstraZeneca the fourth pharmaceutical company in less than a year to settle foreign bribery-related allegations concerning China with US market regulators. Without admitting or denying wrongdoing, AstraZeneca will pay a $375,000 fine in addition to $5.1 million in disgorgement and interest, according to the SEC. Payments of disgorgement are tax-deductible in the United States. Under the 1977 Foreign Corrupt Practices Act, companies and people under US jurisdiction are prohibited from paying bribes in foreign countries to win business. Similar statutes have since been enacted in most developed countries.
Comments
Comments are closed.